CD8A and neoplasm: Moreover, compared to control-treated tumours, the combination of α-PD-1 and PARP14i demonstrated a significant increase of CD4+ and CD8 + T cells expressing surface inhibitory receptors PD-1, TIM-3, and LAG-3 (Fig. 6F–I).